Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 241-245 , November 2009

MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: The feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence

  • Tobias Franiel

      Affiliations

    • Department of Radiology, Charité – Universitätsmedizin Berlin, Germany
    • Corresponding Author InformationCorresponding author. Address: Department of Radiology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
    • ,
  • Lutz Lüdemann

      Affiliations

    • Department of Radiotherapy, Charité – Universitätsmedizin Berlin, Germany
    • ,
  • Matthias Taupitz

      Affiliations

    • Department of Radiology, Charité – Universitätsmedizin Berlin, Germany
    • ,
  • Dirk Böhmer

      Affiliations

    • Department of Radiotherapy, Charité – Universitätsmedizin Berlin, Germany
    • ,
  • Dirk Beyersdorff

      Affiliations

    • Department of Radiology, Charité – Universitätsmedizin Berlin, Germany

Received 8 August 2008 ,Revised 31 July 2009 ,Accepted 11 August 2009.

References 

  1. Mettlin CJ, Murphy GP, McDonald CJ, Menck HR. The National Cancer Data base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the US. Cancer. 1999;86:1877–1882
  2. Roach M. Commentary on a multi-institutional analysis of external beam radiotherapy for T1–T2 prostate cancer: “love the one you’re with” and “do the right thing”. Int J Radiat Oncol Biol Phys. 2003;57:907–909
  3. Hanlon AL, Pinover WH, Horwitz EM, Hanks GE. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys. 2001;50:845–849
  4. Cavanagh W, Blasko JC, Grimm PD, Sylvester JE. Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol. 2000;18:160–165
  5. Sala E, Eberhardt SC, Akin O, et al. Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology. 2006;238:176–183
  6. Coakley FV, Teh HS, Qayyum A, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology. 2004;233:441–448
  7. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:425–430
  8. Pucar D, Shukla-Dave A, Hricak H, et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology. 2005;236:545–553
  9. Rouviere O, Valette O, Grivolat S, et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor–correlation with biopsy findings. Urology. 2004;63:922–927
  10. Prochnow D, Beyersdorff D, Warmuth C, Taupitz M, Gemeinhardt O, Ludemann L. Implementation of a rapid inversion-prepared dual-contrast gradient echo sequence for quantitative dynamic contrast-enhanced magnetic resonance imaging of the human prostate. Magn Reson Imaging. 2005;23:983–990
  11. Boehmer D, Bohsung J, Eichwurzel I, Moys A, Budach V. Clinical and physical quality assurance for intensity modulated radiotherapy of prostate cancer. Radiother Oncol. 2004;71:319–325
  12. Rohlfing T, Russakoff DB, Denzler J, Mori K, Maurer CR. Progressive attenuation fields: fast 2D–3D image registration without precomputation. Med Phys. 2005;32:2870–2880
  13. Ludemann L, Grieger W, Wurm R, Wust P, Zimmer C. Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn Reson Imaging. 2005;23:833–841
  14. Calamante F, Gadian DG, Connelly A. Delay and dispersion effects in dynamic susceptibility contrast MRI: simulations using singular value decomposition. Magn Reson Med. 2000;44:466–473
  15. Kershaw LE, Buckley DL. Precision in measurements of perfusion and microvascular permeability with T1-weighted dynamic contrast-enhanced MRI. Magn Reson Med. 2006;56:986–992
  16. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–232
  17. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449–458
  18. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging. 2001;14:457–463
  19. Franiel T, Ludemann L, Rudolph B, et al. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol. 2008;43:481–487
  20. Harvey CJ, Blomley MJ, Dawson P, et al. Functional CT imaging of the acute hyperemic response to radiation therapy of the prostate gland: early experience. J Comput Assist Tomogr. 2001;25:43–49
  21. Buckley DL. Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med. 2002;47:601–606
  22. Lissbrant IF, Stattin P, Damber JE, Bergh A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate. 1997;33:38–45
  23. Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A. CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology. 2007;244:486–493
  24. Ludemann L, Prochnow D, Rohlfing T, et al. Simultaneous quantification of perfusion and permeability in the prostate using dynamic contrast-enhanced magnetic resonance imaging with an inversion-prepared dual-contrast sequence. Ann Biomed Eng. 2009;37:749–762
  25. Takamiya R, Weinberg V, Young CD, Sandler H, McLaughlin P, Roach M. A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;56:1073–1078
  26. Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:1047–1055
  27. Pucar D, Hricak H, Shukla-Dave A, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007;69:62–69
  28. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58–61
  29. Cheng L, Cheville JC, Bostwick DG. Diagnosis of prostate cancer in needle biopsies after radiation therapy. Am J Surg Pathol. 1999;23:1173–1183
  30. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys. 2000;48:355–367

PII: S0167-8140(09)00442-3

doi: 10.1016/j.radonc.2009.08.016

Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 241-245 , November 2009

Article Tools

* Image Usage & Resolution